LivaNova (NASDAQ:LIVN) Given New $55.00 Price Target at Robert W. Baird

LivaNova (NASDAQ:LIVN) had its target price decreased by Robert W. Baird from $57.00 to $55.00 in a report released on Thursday morning, Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

Several other research firms have also weighed in on LIVN. Needham & Company LLC raised their price objective on LivaNova from $72.00 to $75.00 and gave the stock a buy rating in a research note on Wednesday, July 31st. Mizuho lifted their target price on shares of LivaNova from $75.00 to $80.00 and gave the company a buy rating in a research note on Thursday, May 2nd. StockNews.com raised LivaNova from a hold rating to a buy rating in a research note on Thursday, April 25th. Finally, Stifel Nicolaus lifted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock a buy rating in a research report on Thursday, July 25th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $65.83.

LivaNova Trading Down 3.6 %

Shares of LivaNova stock traded down $1.67 during mid-day trading on Thursday, hitting $45.31. 1,055 shares of the stock were exchanged, compared to its average volume of 663,539. The company has a 50-day simple moving average of $54.01 and a 200 day simple moving average of $54.42. The company has a current ratio of 3.45, a quick ratio of 2.71 and a debt-to-equity ratio of 0.49. LivaNova has a twelve month low of $42.75 and a twelve month high of $64.47. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -78.30 and a beta of 0.99.

Insider Transactions at LivaNova

In other news, Director Daniel Jeffrey Moore sold 56,623 shares of LivaNova stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the transaction, the director now owns 27,534 shares in the company, valued at approximately $1,655,068.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Hexagon Capital Partners LLC increased its holdings in shares of LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after purchasing an additional 370 shares during the period. Fifth Third Bancorp increased its stake in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Lazard Asset Management LLC bought a new position in LivaNova in the 1st quarter worth $84,000. Headlands Technologies LLC grew its position in LivaNova by 33.3% in the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock worth $93,000 after purchasing an additional 451 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of LivaNova during the 1st quarter worth approximately $94,000. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.